Novo Nordisk justifies the reasoning behind the failed GLP-1 Alzheimer’s trials
By Deena Beasley SAN DIEGO, Dec 2 (Reuters) – Novo Nordisk in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer’s patients based on studies in humans, animals and real-world findings, a top company executive said on Tuesday, acknowledging criticism that Novo’s studies had design flaws. Although the trials failed to show a … Read more